drugset / Trial / NCT01372137
First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NOX-H94
RandomizedFactorialDouble-blindTreatment
Summary
This is the first clinical trial with NOX-H94. The purpose of this clinical trial is to identify a safe and efficacious treatment regimen for the clinical development of NOX-H94 in patients with anemia of chronic disease (inflammation).
Timeline
- Start
- 2011-07
- Primary completion
- 2012-03
- Completion
- 2012-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lexaptepid pegol | Oligonucleotide (other) | 0.3 mg/kg | Intravenous |
| Subject | Lexaptepid pegol | Oligonucleotide (other) | 0.6 mg/kg | Intravenous |
| Subject | Lexaptepid pegol | Oligonucleotide (other) | 1.2 mg/kg | Intravenous |
| Subject | Lexaptepid pegol | Oligonucleotide (other) | 2.4 mg/kg | Intravenous |
| Subject | Lexaptepid pegol | Oligonucleotide (other) | 4.8 mg/kg | Intravenous |